In the News
PPD discusses lab trends at AAPS 2018
Heather Myler of PPD® Laboratories offers her thoughts on labs trends.
PPD unveils new additions in a number of therapeutic areas
PPD strengthens drug development expertise with new therapeutic professionals.
The impact of vortexing on the particle-size distribution of pharmaceuticals
Greg Maj, Jeff Driscoll, Eric Olson and Jonathon Salsbury report on a study that compares the applied shear to sample suspensions of ibuprofen to observe the effects of applied shear on the particle size distribution.
Ensuring Employees’ Well-Being In The Eye Of A Storm
Ron Garrow discusses how in the wake of Hurricane Florence that our employees’ well-being comes first.
An analytical approach to biosimilar drug development
Patricia Hurley, Edward Tabler and Duu-Gong Wu talk about the impact that analytical testing on biosimilars has on their pathway to regulatory approval.
An interview with PPD
Rhonda Henry discusses some of the patient recruitment issues facing the clinical trials industry.
Challenging the ‘site-first’ status quo in patient enrollment
Tammy D’Lugin-Monroe and Dan Brunwasser highlight a new patient-centric enrollment model that uses a data-driven approach to identify qualified patients first.
Patient centricity: Moving from a ‘nice to have’ to best practice
Rhonda Henry discusses the concept of putting the patient “front and center.”
PPD flips the patient enrollment model and launches new site solution
Roger Smith discusses how SynexusPlus and PatientAdvantage will enhance PPD’s enrollment capabilities.